Organon & Co. (OGN) Expected to Release Quarterly Earnings on Monday

Organon & Co. (NYSE:OGN) is expected to be posting its Q3 2026 resultson Monday, November 9th. Analysts expect Organon & Co. to post earnings of $0.88 per share and revenue of $1.58 billion for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, October 30, 2026 at 7:00 AM ET.

Organon & Co. Trading Down 0.0%

Shares of Organon & Co. stock opened at $13.84 on Monday. Organon & Co. has a 52 week low of $5.69 and a 52 week high of $13.84. The company has a debt-to-equity ratio of 8.43, a quick ratio of 1.44 and a current ratio of 1.95. The stock has a 50 day moving average price of $13.74 and a two-hundred day moving average price of $11.47. The stock has a market capitalization of $3.63 billion, a PE ratio of 18.20, a price-to-earnings-growth ratio of 1.27 and a beta of 1.53.

Organon & Co. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Stockholders of record on Monday, November 9th will be given a $0.02 dividend. The ex-dividend date of this dividend is Monday, November 9th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s payout ratio is 10.39%.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Five equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $11.40.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.